For the quarter ending 2025-09-30, MNPR had $88,175,424 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,437,601 | -5,078,498 |
| Stock-based compensation expense, net | 1,099,210 | 2,634,563 |
| Other current assets | 107,242 | 586,757 |
| In-process research and development accrued expenses | 0 | 3,000,000 |
| Accounts payable, accrued expenses and other current liabilities | 355,101 | -705,565 |
| Operating lease right-of-use assets and liabilities, net | 0 | 4,430 |
| Net cash used in operating activities | -2,090,532 | -6,740,687 |
| Purchase of short-term investments | 5,726,027 | 3,138,534 |
| Maturities of short-term investments | 3,600,000 | 4,000,000 |
| Net cash used in investing activities | -2,126,027 | 861,466 |
| Cash proceeds from the sales of common stock under a capital on demandtm sales agreement | 0 | 0 |
| Taxes paid related to net share settlement of vested restricted stock units | 381,563 | 452,684 |
| Cash proceeds from the issuance of common stock upon exercise of stock options | 214 | 20,157 |
| Net proceeds from issuance of common stock and concurrent issuance of pre-funded warrants upon public offering, net of offering costs | 127,772,915 | - |
| Repurchase of common stock | 34,999,957 | - |
| Net cash provided by financing activities | 92,391,609 | -432,527 |
| Effect of exchange rates | 376 | -2,605 |
| Net increase (decrease) in cash and cash equivalents | 88,175,424 | -6,314,353 |
| Cash and cash equivalents at beginning of period | 45,816,289 | - |
| Cash and cash equivalents at end of period | 127,677,360 | - |
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)